Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Last trade$9.07
Day change-$0.09 (-0.98%)
Day range$8.84 – $9.30
Volume587,102
Market cap$783M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$782.72M
Price / earnings
—
Price / book
1.58×
Price / sales
11.13×
EV / sales
10.49×
EV / EBITDA
-5.17×
Profitability
Earnings per share
-$1.53
Return on assets
-18.77%
Return on equity
-26.39%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
10.32×
Quick ratio
10.32×
Cash ratio
0.73×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$174.39M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GLUE, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$54.37M
$8.97M
$4.21M
$2.78M
$12.77M
$23.19M
$84.93M
$60.65M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$54.37M
$8.97M
$4.21M
$2.78M
$12.77M
$23.19M
$84.93M
$60.65M
Selling, general and administrative
$10.94M
$10.13M
$10.18M
$10.52M
$9.07M
$8.1M
$8.7M
$8.78M
Research and development
$45.36M
$47.96M
$44.07M
$41.98M
$36.68M
$30.65M
$32.19M
$38.87M
Total operating expenses
$56.31M
$58.1M
$54.24M
$52.5M
$45.74M
$38.75M
$40.89M
$47.64M
Operating income
-$1.94M
-$49.13M
-$50.03M
-$49.72M
-$32.98M
-$15.55M
$44.04M
$13M
Interest expense
$5.63M
$5.92M
$0
$0
$2.75M
$3.07M
$0
$0
Income before taxes
$3.78M
-$43.19M
-$44.45M
-$46.08M
-$30.26M
-$11.1M
$47.71M
$15.6M
Income taxes
$716K
$208K
$52K
$59K
-$3.18M
$1.2M
$822K
$2.16M
Net income
$3.06M
-$43.4M
-$44.5M
-$46.14M
-$27.08M
-$12.3M
$46.89M
$13.44M
Net income attributable to common shareholders
$3.06M
-$43.4M
-$44.5M
-$46.14M
-$27.08M
-$12.3M
$46.89M
$13.44M
EBITDA
$205K
-$47.22M
-$48.01M
-$47.63M
-$30.88M
-$13.43M
$46.08M
$15.07M
Basic earnings per share
$0.03
-$0.43
-$0.45
-$0.54
-$0.33
-$0.15
$0.57
$0.16
Diluted earnings per share
$0.03
-$0.43
-$0.45
-$0.54
-$0.33
-$0.15
$0.57
$0.16
Recent news
Company coverage with links to the original publishers.
Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102, showing significant NEK7 degradation and reduction in cardiovascular disease markers with safety comparable to placebo. The company plans to initiate three Phase 2 studies in gout, coronary artery disease, and hidradenitis suppurativa. Additionally, Novartis initiated Phase 2 studies of partnered program MRT-6160 in Sjögren's disease and psoriatic arthritis, triggering $87.5 million in milestone payments. The company maintains a strong cash position of $582.6 million, expected to support operations into 2029.
Precigen (PGEN) reported Q3 2026 earnings of $0.08 per share, missing the consensus estimate of $0.09, though revenues of $74.15 million exceeded expectations. The stock has outperformed the S&P 500 by 15% year-to-date and holds a Zacks Rank #3 (Hold) rating. Monte Rosa Therapeutics (GLUE) is expected to report a quarterly loss of $0.10 per share with revenues projected at $45.33 million.
Monte Rosa Therapeutics (GLUE) has gained 3.5% over the past four weeks and currently trades at $10.63. Wall Street analysts have set a mean price target of $26.88, indicating a potential 152.9% upside. The stock has a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions over the last 30 days. However, the article cautions that price targets alone should not be the sole basis for investment decisions, as analysts often set overly optimistic targets.
Options traders are pricing in significant volatility for Monte Rosa Therapeutics (GLUE), with the December 18, 2026 $20.00 call showing high implied volatility. However, the company holds a Zacks Rank #4 (Sell) rating. Recent analyst activity shows improving earnings estimates, with consensus moving from a 26-cent loss to a 10-cent loss per share over the last 60 days, suggesting potential for a developing trade opportunity.
The molecular glues market is experiencing significant growth with over 80 active players developing 90+ pipeline candidates. Key companies including Revolution Medicines, Gluetacs Therapeutics, Captor Therapeutics, and others are advancing promising molecular glue degraders across oncology, immunology, and neurodegenerative diseases. Recent developments include FDA Breakthrough Therapy Designation for Daraxonrasib and multiple clinical trial initiations, positioning molecular glues as a promising therapeutic strategy for previously undruggable proteins.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.